TO THE EDITOR:
We read with great consternation the clinical guidelines by Krantz and colleagues (1) advocating rate-corrected QT interval (QTc) screening for methadone treatment. In our opinion, not only are the recommendations short-sighted and irresponsible, but they are also detrimental to society at large.
We foresee multidimensional problems with these guidelines. First, Krantz and colleagues do not appreciate that, for most opioid users (both former substance abusers and pain patients), methadone represents a last-resort treatment. Therefore, even if a prolonged QT interval is found, the likelihood that an equally effective alternative treatment could be implemented is remote (2) .
Second, compared with the other potentially catastrophic risks associated with methadone, the chance of a fatal arrhythmia is minimal. The side effects and potential complications of opioid use in general far outweigh the marginally increased risk entailed by methadone use (3, 4) . Not only methadone, but also oxycodone, has been associated with the surrogate outcome measure of a prolonged QT interval, suggesting that the full-fledged earthquake (that is, "recommendations" that in essence become restrictive practice mandates because of the litigious nature of our society) may be just over the horizon (5) . Should we then perform serial ECG on every patient who initiates opioid therapy, including on emergency department visits and ambulatory surgical procedures? Or, because the sensitivity of 1 ECG screening is quite low, maybe we need to increase the surveillance interval to every month?
Finally, the guidelines do not address a possible relationship between changes observed on ECG and dose, dosing interval, and treatment duration. Does this imply that a patient taking methadone, 5 mg twice daily, should be treated identically to a patient taking 100 mg three times daily? If so, this would be antithetical to everything we've learned about drug-related toxicity.
We do agree that the surge in methadone use has resulted in a corresponding increase in drug-related deaths. But we have no way of knowing how many of these are due to arrhythmias, misuse, or lack of physician education. We do not live in a society in which time and resources are unlimited, people are altruistic, and cost is irrelevant. Besides cardiologists, the only people likely to benefit from the published recommendations are ECG manufacturers and trial lawyers. Aegis has been serving California communities for more than 10 years and has been using methadone to safely treat more than 5000 patients on a daily basis. Aegis has not encountered any evidence of torsade de pointes attributable to our patients' treatment with methadone. In fact, over more than 30 years (1969 to 2002), only 43 cases of methadone-associated torsade de pointes and 16 cases of QTc prolongation were reported to the U.S. Food and Drug Administration's MedWatch program. In addition, other risk factors for QTc prolongation and torsade de pointes (for example, taking medications with known drug-drug interactions, low potassium or magnesium levels, and structural heart disease) were found in 75% of such cases.
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Furthermore, in the case series (1) mentioned by Krantz and colleagues, approximately 82% (14 of 17) of those patients had known risk factors for arrhythmias, such as hypokalemia, or were concomitantly taking other drugs that could prolong the QTc interval. Therefore, Krantz and colleagues themselves cautioned that "[their] report should not be interpreted to suggest that high-dose methadone cannot be used safely."
Both Aegis' strict internal policies and state regulatory requirements dictate that Aegis physicians perform a thorough review of all patient deaths. Therefore, Aegis receives and reviews a coroner's report in conjunction with each patient death. Aegis physicians are also in direct communication with the primary care physicians of their patients. Neither the communications concerning the care of thousands of patients nor the reviewed coroners' reports have ever indicated any correlation between QTc prolongation and the treatment of our patients with methadone. Nonetheless, to effectively and reasonably address concerns raised by Krantz and colleagues, Aegis has updated its clinical risk management policy to require ECG for all patients treated with methadone doses greater than 150 mg, or for patients with established cardiovascular disease.
Treatment with methadone has both costs and benefits. Over the past 40 years, methadone has been firmly established as the most effective therapy for opiate addiction and has been linked to a substantial reduction in the mortality rates of patients with opiate addiction. We believe that a broad and sweeping requirement that all prospective and continuing patients undergo ECG is a dangerous obstacle and deterrent to their recovery efforts.
The relatively small potential risk for adverse cardiac effects must be considered against the serious risks that would result from withholding methadone treatment (for example, continued illicit drug use and public health issues). If ECG were required, thousands of patients who are indigent and uninsured would be forced to withdraw from the program, and prospective patients will be unable to access treatment for the same reason.
Furthermore, Krantz and colleagues should have considered other effective measures to ensure the safety of patients, including education of patients on these concerns, collaboration with primary care physicians, and monitoring of patients with a history of cardiac conditions. Such measures would not have a detrimental effect on access to treatment.
Aegis believes that the medical diagnosis and the determination of a patient's fitness for methadone treatment must be left in the hands of patients' treating physicians. Aegis further believes that Krantz and colleagues neglected to consider the various medical, psychological, and cultural considerations that accompany drug addiction.
We would like to point out the following findings from previous studies and publications regarding the relationship between QTc prolongation and methadone. First, much of the evidence to date regarding QTc prolongation and methadone are the result of case reports and small case studies (1, 2) . Second, many of these cases (82%) did not isolate methadone as the triggering element for QTc prolongation; rather, additional factors that could have played important roles in the diagnosis were not ruled out. QTc prolongation often results from a confluence of risk factors rather than a single causative agent.
Third, the prevalence of other substance abuse, such as cocaine, alcohol, and tobacco, would be expected in opioid-dependent persons entering methadone maintenance therapy. Cocaine has long been related to depression of heart rhythms, and alcohol has been shown to prolong QTc by up to 19%. In addition, many patients in methadone maintenance therapy are treated with multiple drugs that may alter electrical conduction in heart muscle tissue.
Fourth, past clinical investigations have shown minimal effects of methadone on QTc prolongation (3, 4) . In a 2003 study of 50 pain patients (5), QTc intervals did not change during oral methadone therapy. Fifth, researchers have noted that 89% of plasma methadone is protein-bound, thereby possibly reducing the in vivo amount of methadone available to inhibit IHERG to 11% (free fraction) and increasing the therapeutic index for methadone approximately 10-fold.
Sixth, laboratory studies are often based on methadone blood concentrations nearly 9 times greater than usual therapeutic levels recommended for patients on methadone maintenance therapy. In addition, past studies have been limited to cell cultures or animals, which do not necessarily translate to clinical effects on patients. Furthermore, in many case studies, high doses of methadone were applied directly to heart tissue on a single-dose basis. This is inconsistent with the actual long half-life of methadone and the steady blood serum levels common with methadone maintenance therapy.
Finally, effects on the heart's electrical conduction are not always harmful. In fact, certain opioids (including methadone) have shown cardioprotective effects and have been important adjuncts in treating heart attacks and coronary artery disease (6, 7).
The calcium-slowing effects of methadone may be analogous to the actions of certain heart medications that suppress some forms of arrhythmia (8) . One study (9) found similarities between methadone and verapamil. Verapamil, a calcium-channel blocker used to treat hypertension and angina, has not appeared on any lists of agents known to prolong QTc or induce torsade de pointes; in fact, calcium-channel blocking may shorten the QTc interval.
TO THE EDITOR:
The clinical guidelines by Krantz and colleagues (1) raise important methodological concerns. Although Krantz and colleagues use a method for predicting adverse drug reactions, they neglect to use data extraction and quality assessment tools. In fact, they state that they "did not prespecify critical appraisal criteria." This is contrary to Annals' "Information for Authors" (2), which requires guidelines to include a grading system, such as those described by the Conference on Guideline Standardization; the Grading of Recommendations Assessment, Development and Evaluation Working Group; or the U.S. Preventive Services Task Force (USPSTF).
On review of the 212 articles listed in Annals' online "Clinical Guidelines/Position Papers" collection (accessed 9 February 2009), I found 94 unique clinical guidelines. Excluding 2 updates on adult vaccination schedules, 54 of the remaining 92 guidelines used a grading system, whereas 28 guidelines systematically rated the quality of evidence supporting guideline recommendations. Eight of the 10 guidelines providing neither grade nor quality assessment were published before 1998, when such quality assessments became routine. Therefore, the guidelines by Krantz and colleagues are 1 of 2 guidelines published by Annals since 1998 that do not explicitly evaluate or grade the quality of evidence used in guideline recommendations. Using USPSTF criteria (3), the literature cited by Krantz and colleagues would result in a grade of I, indicating that the evidence is insufficient to determine the relationship between the benefits and harms of QTc screening. Had the authors expounded on this and incorporated recent methods (published in Annals) (4) for guidelines based on insufficient evidence, the reader would be better equipped to make rational clinical decisions.
Of further interest, although Krantz and colleagues summarize their recommendations in Table 2 under the title "Consensus Recommendations," 2 of the panelists have declined acknowledgment in the publication, which raises the question: Was there consensus?
In addition, the online version (but not the print version) of this article states that 3 of the panel members have financial conflicts of interest related to support by Reckitt Benckiser (1 was formerly President and CEO), the producer of methadone's main competitor (buprenorphine) in the treatment of opiate dependence. These disclosures were not made in the original, withdrawn version of the guidelines.
These issues call into question the quality of Krantz and colleagues' recommendations, the independence of the authors, and the judgment of Annals in publishing clinical guidelines that fall well outside the normative standards.
Gavin Bart, MD Hennepin County Medical Center Minneapolis, MN 55415
IN RESPONSE: We appreciate the many thoughtful and provocative comments on our consensus guideline for QTc interval screening in methadone treatment. The common theme was a strong endorsement of methadone's role as a cornerstone therapy in opioid addiction. Dr. Byrne and Drs. Cohen and Mao rightly assert that methadone may be a treatment of last resort with limited therapeutic alternatives. We agree and clearly acknowledge in our guideline that Letters methadone is a niche medication (1) that must remain widely available despite the many alternative drugs for treatment of chronic pain and a second approved therapy, buprenorphine, in the addiction field. Indeed, our guideline does not mandate switching to an alternative therapy, even in the setting of marked (Ͼ500 ms) methadoneinduced QTc prolongation. Instead, we suggest a measured approach of risk stratification that informs both a risk-benefit discussion as well as many individualized clinical actions to mitigate risk.
Dr. Girgis highlights the disproportionate increase in methadone-associated deaths in recent forensic studies (2) . Specifically, he notes that coroners' reports have not indicated a link between unexplained methadone-associated sudden death and the QTc interval. This is not surprising, because ECG data obtained before sudden cardiac death are rarely available to coroners. However, a recent autopsy cohort study by Chugh and colleagues (3) suggests that methadone-associated sudden deaths may have been the result of a fatal arrhythmia, because of the relative lack of structural heart disease in persons with modest serum methadone concentrations. Finally, Dr. Girgis cites the work of Lipski and colleagues (4) to suggest that methadone has minimal effect on the QTc interval. We respectfully disagree with this characterization, because 34% of methadone-treated patients in this study had significant QTc prolongation compared with only 18% of methadone-naive drug abusers.
We thank Dr. Bart for pointing out the inherent methodological limitations of our guideline. We acknowledge that the number and types of studies available regarding methadone cardiotoxicity are limited and do not lend themselves to critical appraisal criteria, metaanalytic techniques, or other quantitative quality assessments. Despite these inherent limitations, we adopted a validated clinical tool (5) to determine with certainty the link between methadone and torsade de pointes as a prerequisite to asserting the need for a risk mitigation strategy. Safeguarding patients from potentially fatal drug-induced arrhythmia creates a very different contextual framework than grading evidence for screening and treatment decision algorithms, such as the USPSTF guidelines that Dr. Bart alludes to. It is therefore no surprise that we found no evidence-based guideline recommendations from the USPSTF regarding mitigation of druginduced torsade de pointes on review of the scientific literature (PubMed, accessed 10 May 2009). We are also unaware of any "effectiveness" evaluations of risk mitigation strategies that require ECG screening for drugs independently associated with torsade de pointes (6), including the methadone derivative levacetylmethadol (7). Finally, no scientific objections were raised to our recommendations during any of the cardiac expert panel meetings convened by the Center for Substance Abuse Treatment. Nonetheless, we respect the autonomy of clinicians to either change their views or decline acknowledgment. This in no way calls into question the integrity of the research process, the clinical science behind our guideline, or the editorial judgment in publishing it.
In conclusion, methadone is associated with a dramatic increase in deaths and cardiac arrhythmias. Arrhythmic events have often been associated with high doses of methadone or concurrent illicit drug use. Many patients in the addiction field fit into these categories, which underscores the importance of defining risk with ECG. We believe it is the increase in methadone deaths that imperils the future of methadone treatment rather than ECG monitoring, which is relatively simple, noninvasive, and inexpensive. The opioid treatment and pain management communities therefore must consider appropriate measures to address this challenge. Understanding the complex pharmacokinetic and pharmacodynamic properties of methadone (especially QTc prolongation) is an essential first step. Disclosure of arrhythmia risk to patients, ECG screening, and risk stratification that informs individualized treatment decisions are responsible next steps to ensure safety in this vulnerable population.
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